Amylyx Pharmaceuticals (AMLX) said Thursday that it has designated AMX0318 as a development candidate for post-bariatric hypoglycemia, and other rare diseases.
The company said AMX0318 was selected as part of a research collaboration agreement with Danish preclinical contract research Gubra, which will receive a $4 million milestone payment for the selection.
Under the terms of the collaboration, Gubra is eligible to receive more than $50 million in success-based development and commercialization milestones, as well as mid-single digit royalties on global net sales.
Shares of Amylyx were up more than 3% pre-bell.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments